Rain Enhancement Technologies Holdco, Inc. (RAIN) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the Reign Oncology, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode, and following the presentation, we will conduct a question-and-answer session. If at any time during the call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, August 10, 2023. I would now like to turn the conference call over to Mr. Dan Barry of LifeSci Advisors, please go ahead. Thank you, Operator, and good afternoon, everyone. With me today on the phone is Avinash Valenki, Chief Executive Officer of Raid Oncology, and Nelson Cabochon, Acting SVP of Finance. Following the call, Dr. Robert Doble, Chief Scientific Officer and Chief Medical Officer, will be joining Avinash and Nelson for a short Q&A. Earlier today, RAINN issued a news release announcing the company's results for the second quarter of 2023. Copies of this news release and SEC filings can be found in the Investors section of our website. Full details on updates from the quarter can be found in our news release and 10-Q issued today. Before we begin, I would like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon RAINN's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Action results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in RAINN's most recent quarterly reports on Form 10-Q and annual report on Form 10-K filed with the Se...